Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his move into the leadership role late last year. Amplia is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/amplia-therapeutics-ceo-outlines-2023-milestones-938374502